Cargando…

Sodium-glucose co-transporter 1 (SGLT1) differentially regulates gluconeogenesis and GLP-1 receptor (GLP-1R) expression in different diabetic rats: a preliminary validation of the hypothesis of “SGLT1 bridge” as an indication for “surgical diabetes”

BACKGROUND: Sodium-glucose co-transporter 1 (SGLT1) may play a synergistic role in gluconeogenesis (GNG) and glucagon-like peptide-1 (GLP-1) expression. We proposed the hypothesis of a “SGLT1 bridge” as an indication for “surgical diabetes” that was preliminary validated in the present study. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hengliang, Cai, Huajie, Wang, Xiaokun, Chen, Tao, Zhen, Chaohui, Zhang, Zhenzhan, Ruan, Xiaojiao, Li, Guoxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096370/ https://www.ncbi.nlm.nih.gov/pubmed/35571394 http://dx.doi.org/10.21037/atm-22-1769

Ejemplares similares

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022)

Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction
por: Trombara, Filippo, et al.
Publicado: (2023)

FRI648 GLP-1RA And SGLT2i Treatments May Show Improved Depression Metrics In Diabetes Treatment
por: Jain, Arad, et al.
Publicado: (2023)

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
por: Lee, Eun Young, et al.
Publicado: (2015)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

Monitoring the Comparative Safety of SGLT2i vs GLP-1 RA in Older Adults With Type 2 Diabetes by Frailty Status
por: Kutz, Alexander, et al.
Publicado: (2021)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms
por: Hussein, Abdelaziz M., et al.
Publicado: (2020)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

SAT-662 Effects of SGLT Inhibitors or GLP1 Analogues on Glucose Homeostasis and Body Weight in Patients with Type 1 Diabetes: A Network Meta-Analysis
por: Lim, Soo, et al.
Publicado: (2020)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
por: Gourdy, Pierre, et al.
Publicado: (2023)

Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
por: Koike, Masao, et al.
Publicado: (2021)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
por: Uneda, Kazushi, et al.
Publicado: (2021)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oolrg5blet2l9slo2nbr4isjtu